Senior Medical Director, Clinical Development

Sr. Medical Director Clinical Development

Northern New Jersey (Hybrid 3x per week on-site)

Compensation: $,000 + Bonus + Equity

An industry-leading biotech with a proprietary discovery platform and a proven leadership team behind one of the most transformative immuno-oncology approvals is looking for a Sr. Medical Director Clinical Development. The company boasts a robust pipeline with multiple late-stage programs and over 10 additional indications, spanning oncology, neurology, and immunology. Backed by top-tier investors and a multi-year cash runway, they are well-positioned for rapid growth and significant impact.

• Design and lead early‑stage clinical development trials, including assessment of safety and efficacy data, medical monitoring, and other clinical study activities.
• Collaborate with biomarker, discovery, and translational research teams to integrate scientific insights into clinical development.
• Interpret study data and reports, and prepare high‑quality written and oral presentations of research findings.
• Contribute to program‑level strategy discussions within Eikon's therapeutic focus areas.
• Work closely with Clinical Science, discovery, translational, biomarker research, toxicology, clinical pharmacology, drug safety, regulatory, Global Clinical Operations, and supporting functions to ensure seamless cross‑functional execution.
• Build strong working relationships with external investigators, key opinion leaders, and alliance partners.
• Partner with Data Management, Clinical Operations, Biostatistics, and Regulatory to ensure strategic, coordinated, and high‑quality execution of clinical protocols.
• Collaborate with study physicians and clinical scientists to develop rigorous study protocols and ensure consistent processes and standards across programs.
• Support responses to protocol‑related questions from health authorities and ethics committees in coordination with functional partners.

• Medical degree (MD) with fellowship in Oncology.